Lineage Cell Therapeutics, Inc. (LCTX): Price and Financial Metrics

LCTX POWR Grades

• LCTX scores best on the Value dimension, with a Value rank ahead of 46.42% of US stocks.
• LCTX's strongest trending metric is Stability; it's been moving down over the last 179 days.
• LCTX ranks lowest in Momentum; there it ranks in the 12th percentile.

LCTX Stock Summary

• Lineage Cell Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 9.38% of US listed stocks.
• LCTX's price/sales ratio is 59.03; that's higher than the P/S ratio of 96.54% of US stocks.
• As for revenue growth, note that LCTX's revenue has grown 137.73% over the past 12 months; that beats the revenue growth of 94.28% of US companies in our set.
• Stocks that are quantitatively similar to LCTX, based on their financial statements, market capitalization, and price volatility, are ZSAN, SPRO, GSIT, ATNM, and EVGN.
• Visit LCTX's SEC page to see the company's official filings. To visit the company's web site, go to www.lineagecell.com.

LCTX Valuation Summary

• LCTX's EV/EBIT ratio is -27.2; this is 192.83% lower than that of the median Healthcare stock.
• Over the past 243 months, LCTX's EV/EBIT ratio has gone down 13.5.
• LCTX's EV/EBIT ratio has moved down 13.5 over the prior 243 months.

Below are key valuation metrics over time for LCTX.

LCTX Growth Metrics

Its 4 year net income to common stockholders growth rate is now at -9.49%.
• Its 4 year cash and equivalents growth rate is now at -63.76%.
• The 3 year net income to common stockholders growth rate now stands at 204.79%.

LCTX's revenue has moved up $799,000 over the prior 52 months.

The table below shows LCTX's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-12-31	4.341	-23.561	-43.019
2021-09-30	3.528	-23.329	-11.995
2021-06-30	1.829	-23.328	-11.932
2021-03-31	1.703	-22.151	-13.666
2020-12-31	1.826	-19.753	-20.649
2020-09-30	2.712	-19.635	-27.163

LCTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• LCTX has a Quality Grade of D, ranking ahead of 12.26% of graded US stocks.
• LCTX's asset turnover comes in at 0.015 -- ranking 380th of 682 Pharmaceutical Products stocks.
• INFI, ATHX, and TTNP are the stocks whose asset turnover ratios are most correlated with LCTX.

The table below shows LCTX's key quality metrics over time.